- Home
- MDGL vs DCI Comparison
MDGL vs DCI Comparison
Compare MDGL & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | DCI |
|---|---|---|
| Founded | 2011 | 1915 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pollution Control Equipment |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.5B |
| IPO Year | 2005 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MDGL | DCI |
|---|---|---|
| Price | $476.16 | $83.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $674.45 | $99.00 |
| AVG Volume (30 Days) | 255.0K | ★ 739.7K |
| Earning Date | 05-06-2026 | 06-02-2026 |
| Dividend Yield | N/A | ★ 1.38% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ 2.75 |
| Revenue | $180,133,000.00 | ★ $2,844,900,000.00 |
| Revenue This Year | $58.39 | $4.58 |
| Revenue Next Year | $48.55 | $5.18 |
| P/E Ratio | ★ N/A | $30.39 |
| Revenue Growth | N/A | ★ 4.05 |
| 52 Week Low | $275.00 | $67.71 |
| 52 Week High | $615.00 | $112.84 |
Technical Indicators
Market Signals| Indicator | MDGL | DCI |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 46.88 |
| Support Level | $456.39 | $83.13 |
| Resistance Level | $502.97 | $88.43 |
| Average True Range (ATR) | 19.13 | 2.09 |
| MACD | -3.10 | 0.23 |
| Stochastic Oscillator | 34.03 | 49.85 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.